Natural History of MYH7-Related Dilated Cardiomyopathy
- PMID: 36007715
- DOI: 10.1016/j.jacc.2022.07.023
Natural History of MYH7-Related Dilated Cardiomyopathy
Abstract
Background: Variants in myosin heavy chain 7 (MYH7) are responsible for disease in 1% to 5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described.
Objectives: We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression.
Methods: We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% female; 35.6 ± 19.2 years) recruited from 29 international centers.
Results: At initial evaluation, 106 (72.1%) patients had DCM (left ventricular ejection fraction: 34.5% ± 11.7%). Median follow-up was 4.5 years (IQR: 1.7-8.0 years), and 23.7% of carriers who were initially phenotype-negative developed DCM. Phenotypic expression by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years of age. Thirty-six percent of patients with DCM met imaging criteria for LV noncompaction. During follow-up, 28% showed left ventricular reverse remodeling. Incidence of adverse cardiac events among patients with DCM at 5 years was 11.6%, with 5 (4.6%) deaths caused by end-stage heart failure (ESHF) and 5 patients (4.6%) requiring heart transplantation. The major ventricular arrhythmia rate was low (1.0% and 2.1% at 5 years in patients with DCM and in those with LVEF of ≤35%, respectively). ESHF and major ventricular arrhythmia were significantly lower compared with LMNA-related DCM and similar to DCM caused by TTN truncating variants.
Conclusions: MYH7-related DCM is characterized by early age of onset, high phenotypic expression, low left ventricular reverse remodeling, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, which are rare.
Keywords: MYH7; dilated cardiomyopathy; genetics.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI18/0004, PI20/0320, and PT17/0015/0043 (cofunded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the ISCIII, MCIN, the Pro-CNIC Foundation, and the Severo Ochoa Centers of Excellence program (CEX2020-001041-S). The Hospital Universitario Puerta de Hierro, the Hospital Sant Joan de Déu, and the Hospital Universitario Virgen de la Arrixaca are members of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart. Dr de Frutos receives grant support from ISCIII (CM20/00101). Genetic examinations of Polish patients were funded with DETECTIN-HF grant from the ERA-CVD framework, NCBiR. Dr Baas has received funding from CVON2020B005 DOUBLE-DOSE, Dutch Heart Foundation (Dekker 2015T041). Dr Fatkin has received funding from Victor Chang Cardiac Research Institute and NSW Health. Dr Lopes is funded by an MRC UK Clinical Academic Research Partnership award (MR/T005181/1). Dr Meder has received funding from the Deutsches Zentrum für Herz-Kreislauf-Forschung (German Center for Cardiovascular Research) and Informatics for Life (Klaus Tschira Foundation). Dr Kubanek has received grant support from the Ministry of Health, Czech Republic (NV19-08-00122) and IPO (Institute for Clinical and Experimental Medicine–IKEM, IN 00023001). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment in
-
Myosin-Related Dilated Cardiomyopathy: Another Elephant Emerges From Darkness.J Am Coll Cardiol. 2022 Oct 11;80(15):1462-1464. doi: 10.1016/j.jacc.2022.08.749. J Am Coll Cardiol. 2022. PMID: 36202535 Free PMC article. No abstract available.
Similar articles
-
Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy.J Am Heart Assoc. 2024 Nov 5;13(21):e036208. doi: 10.1161/JAHA.124.036208. Epub 2024 Nov 4. J Am Heart Assoc. 2024. PMID: 39494569 Free PMC article.
-
Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling.Sci Rep. 2018 Jan 31;8(1):1998. doi: 10.1038/s41598-018-20114-9. Sci Rep. 2018. PMID: 29386531 Free PMC article.
-
Penetrance and Prognosis of MYH7 Variant-Associated Cardiomyopathies: Results From a Dutch Multicenter Cohort Study.JACC Heart Fail. 2024 Jan;12(1):134-147. doi: 10.1016/j.jchf.2023.07.007. Epub 2023 Aug 9. JACC Heart Fail. 2024. PMID: 37565978
-
Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals.Clin Res Cardiol. 2017 Feb;106(2):127-139. doi: 10.1007/s00392-016-1033-6. Epub 2016 Aug 30. Clin Res Cardiol. 2017. PMID: 27576561 Review.
-
Genetic mutations and mechanisms in dilated cardiomyopathy.J Clin Invest. 2013 Jan;123(1):19-26. doi: 10.1172/JCI62862. Epub 2013 Jan 2. J Clin Invest. 2013. PMID: 23281406 Free PMC article. Review.
Cited by
-
Research landscape of genetics in dilated cardiomyopathy: insight from a bibliometric analysis.Front Cardiovasc Med. 2024 Jul 12;11:1362551. doi: 10.3389/fcvm.2024.1362551. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39070560 Free PMC article.
-
The Genetic Factors Influencing Cardiomyopathies and Heart Failure across the Allele Frequency Spectrum.J Cardiovasc Transl Res. 2024 Oct;17(5):1119-1139. doi: 10.1007/s12265-024-10520-y. Epub 2024 May 21. J Cardiovasc Transl Res. 2024. PMID: 38771459 Free PMC article. Review.
-
Knockout of the Staphylococcus aureus virulence gene sdrC promotes Myh7 expression to inhibit the progression of osteomyelitis.J Mol Histol. 2025 Jun 5;56(3):185. doi: 10.1007/s10735-025-10447-x. J Mol Histol. 2025. PMID: 40471432
-
The Role of Genetics in the Management of Heart Failure Patients.Int J Mol Sci. 2023 Oct 16;24(20):15221. doi: 10.3390/ijms242015221. Int J Mol Sci. 2023. PMID: 37894902 Free PMC article. Review.
-
Case Report: Practice of whole-course pharmaceutical care: a case in hypertrophic cardiomyopathy and a review of the pharmacist's role.Front Cardiovasc Med. 2025 Jul 10;12:1512784. doi: 10.3389/fcvm.2025.1512784. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40709199 Free PMC article.